Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.

Cellular Src activity modulates cell migration, proliferation, and differentiation, and recent reports suggest that individual members of the Src family may play specific roles in these processes. As we have found that Lyn, but not Fyn, activity promotes migration of glioblastoma cells in response to the cooperative signal generated by platelet-derived growth factor receptor beta and integrin alpha(v)beta3, we compared the activity and expression of Lyn and Fyn in glioblastoma (grade IV) tumor biopsy samples with that in anaplastic astrocytoma (grade III) tumors, nonneoplastic brain, and normal autopsy brain samples. Lyn kinase activity was significantly elevated in glioblastoma tumor samples. Notably, the Lyn kinase activity accounted for >90% of pan-Src kinase activity in glioblastoma samples but only approximately 30% of pan-Src kinase activity in the other groups. The levels of phosphorylation of the autophosphorylation site were consistent with significantly higher Lyn activity in glioblastoma tumor tissue than nonneoplastic brain. Although the normalized levels of Lyn protein and the relative levels of Lyn message were significantly higher in glioblastoma samples than nonneoplastic brain, the normalized levels of Lyn protein did not correlate with Lyn activity in the glioblastoma samples. There was no significant difference in the normalized levels of c-Src and Fyn protein and message in the glioblastoma and nonneoplastic brain. Immunostaining revealed that Lyn is located primarily in the glioblastoma cells in the tumor biopsies. These data indicate that Lyn kinase activity is significantly elevated in glioblastoma tumors and suggest that it is the Lyn activity that promotes the malignant phenotype in these tumors.

[1]  G. Gallick,et al.  Src family kinases in tumor progression and metastasis , 2003, Cancer and Metastasis Reviews.

[2]  Q. Ding,et al.  The Pattern of Enhancement of Src Kinase Activity on Platelet-derived Growth Factor Stimulation of Glioblastoma Cells Is Affected by the Integrin Engaged* , 2003, Journal of Biological Chemistry.

[3]  Xianglin Shi,et al.  The SH4-Unique-SH3-SH2 domains dictate specificity in signaling that differentiate c-Yes from c-Src , 2003, Journal of Cell Science.

[4]  K. Mikoshiba,et al.  Impairment of N-methyl-d-aspartate receptor-controlled motor activity in LYN-deficient mice , 2003, Neuroscience.

[5]  G. Gillespie,et al.  Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. , 2002, Cancer research.

[6]  F. Giancotti,et al.  EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes , 2001, The Journal of cell biology.

[7]  B. Jiang,et al.  The intrinsic ability of AFAP-110 to alter actin filament integrity is linked with its ability to also activate cellular tyrosine kinases , 2001, Oncogene.

[8]  M. Resh,et al.  Tyrosine phosphorylation of p190 RhoGAP by Fyn regulates oligodendrocyte differentiation. , 2001, Journal of neurobiology.

[9]  D. Flynn,et al.  The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity , 2001, Oncogene.

[10]  S. Akira,et al.  SHPS‐1 regulates integrin‐mediated cytoskeletal reorganization and cell motility , 2000, The EMBO journal.

[11]  J. Bjorge,et al.  Selected glimpses into the activation and function of Src kinase , 2000, Oncogene.

[12]  A. Ullrich,et al.  Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by Signal-Regulatory Proteins (SIRPs) , 2000, Oncogene.

[13]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[14]  M. Resh,et al.  Morphological Differentiation of Oligodendrocytes Requires Activation of Fyn Tyrosine Kinase , 1999, The Journal of cell biology.

[15]  Sheila M. Thomas,et al.  Regulation of Early Events in Integrin Signaling by Protein Tyrosine Phosphatase SHP-2 , 1999, Molecular and Cellular Biology.

[16]  S. Watson,et al.  Evidence for the involvement of p59fyn and p53/56lyn in collagen receptor signalling in human platelets. , 1999, The Biochemical journal.

[17]  Heung-Chin Cheng,et al.  Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530 , 1999, Oncogene.

[18]  Timothy J. Yeatman,et al.  Activating SRC mutation in a subset of advanced human colon cancers , 1999, Nature Genetics.

[19]  U. Kralisz,et al.  Association of pp60cc‐src with αIIbβ3 in resting platelets , 1998 .

[20]  G. Rijksen,et al.  c‐Src PROTEIN EXPRESSION IS INCREASED IN HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS , 1996, The Journal of pathology.

[21]  B. Pessac,et al.  The Lck Tyrosine Kinase Is Expressed in Brain Neurons , 1996, Journal of neurochemistry.

[22]  S. Curley,et al.  Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  J. Bruner,et al.  Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue , 1995, Journal of Neuroimmunology.

[24]  J. Wilcox,et al.  Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. , 1995, Journal of cell science.

[25]  A. Guha,et al.  Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop , 1995, International journal of cancer.

[26]  D. Schuppan,et al.  Characterization of integrin receptors in normal and neoplastic human brain. , 1993, The American journal of pathology.

[27]  G. Staal,et al.  Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. , 1992, Cancer research.

[28]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[29]  D. Cheresh,et al.  Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. , 1991, The Journal of clinical investigation.

[30]  M. Sudol,et al.  Localization of p62c-yes protein in mammalian neural tissues. , 1991, Oncogene.

[31]  J. Ihle,et al.  Hematopoietic cells express two forms of lyn kinase differing by 21 amino acids in the amino terminus , 1991, Molecular and cellular biology.

[32]  J. Pipas,et al.  pp60c-src activation in human colon carcinoma. , 1989, The Journal of clinical investigation.

[33]  A. Álvarez-Buylla,et al.  Differential developmental expression of cellular yes and cellular src proteins in cerebellum. , 1988, Oncogene research.

[34]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[35]  N. Rosen,et al.  Activation of pp60c-src protein kinase activity in human colon carcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Sudol,et al.  Neuronal localization of the tyrosine-specific protein kinase p62c-yes in rat basal ganglia , 2004, Neurochemical Research.

[37]  Sheila M. Thomas,et al.  Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.